Primary implantation of type i Boston keratoprosthesis in nonautoimmune corneal diseases

Cornea

Volumn 34, Issue 3, 2015, Pages 264-270

  Chang, Han Ying Peggy ^a   Luo, Zhonghui Katie ^a   Chodosh, James ^a   Dohlman, Claes H ^a   Colby, Kathryn A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Primary Boston KPro

Indexed keywords

ANTIBIOTIC AGENT; MOXIFLOXACIN; STEROID; VANCOMYCIN;

ADULT; AGED; AMBLYOPIA; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORNEA DISEASE; CORNEA DYSTROPHY; CORNEA NEOVASCULARIZATION; CORNEAL MELT; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; ENUCLEATION; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; KERATOCONUS; KERATOPATHY; KERATOPROSTHESIS; MALE; MEDICAL DEVICE COMPLICATION; MEDICAL RECORD REVIEW; MICROPHTHALMIA; NERVE PARALYSIS; NYSTAGMUS; OBSERVATIONAL STUDY; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTHESIS IMPLANTATION; RETINA DETACHMENT; RETROPROSTHETIC MEMBRANE FORMATION; SCLERA BUCKLING PROCEDURE; STEROID THERAPY; STRABISMUS; VERY ELDERLY; VISION; VISUAL ACUITY; VITRECTOMY; VITREOUS BIOPSY; VITRITIS; AGED, 80 AND OVER; ARTIFICIAL ORGANS; CORNEAL DISEASES; HUMANS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTHESES AND IMPLANTS; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES;

ADULT; AGED; AGED, 80 AND OVER; ARTIFICIAL ORGANS; CORNEAL DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTHESES AND IMPLANTS; PROSTHESIS DESIGN; PROSTHESIS IMPLANTATION; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84923550671     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000357     Document Type: Article

References (45)

1. Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001;20:19-23.
2. Klufas MA, Colby KA. The Boston keratoprosthesis. Int Ophthalmol Clin. 2010;50:161-175.
3. Colby KA, Koo EB. Expanding indications for the Boston keratoprosthesis. Curr Opin Ophthalmol. 2011;22:267-273.
4. Aldave AJ, Kamal KM, Vo RC, et al. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009; 116:640-651.
5. Zerbe BL, Belin MW, Ciolino JB. Results from the multicenter Boston type 1 Keratoprosthesis Study. Ophthalmology. 2006;113:1779. e1-1779.e7.
6. Traish AS, Chodosh J. Expanding application of the Boston type I keratoprosthesis due to advances in design and improved post-operative therapeutic strategies. Semin Ophthalmol. 2010;25:239-243.
7. Colby KA, Shukla AN. Indications for the Boston keratoprosthesis. In: Holland EJ, Mannis MJ, Lee WB, eds. Ocular Surface Disease: Cornea, Conjunctiva and Tear Film. London, United Kingdom: Elsevier; 2013: 403-406.
8. Thompson RW Jr, Price MO, Bowers PJ, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003;110:1396-1402.
9. Inoue K, Amano S, Oshika T, et al. Risk factors for corneal graft failure and rejection in penetrating keratoplasty. Acta Ophthalmol Scand. 2001; 79:251-255.
10. Halberstadt M, Machens M, Gahlenbek KA, et al. The outcome of corneal grafting in patients with stromal keratitis of herpetic and nonherpetic origin. Br J Ophthalmol. 2002;86:646-652.
11. Al-Swailem SA. Graft failure: II. Ocular surface complications. Int Ophthalmol. 2008;28:175-189.
12. Akpek EK, Harissi-Dagher M, Petrarca R, et al. Outcomes of Boston keratoprosthesis in aniridia: a retrospective multicenter study. Am J Ophthalmol. 2007;144:227-231.
13. Khan BF, Harissi-Dagher M, Pavan-Langston D, et al. The Boston keratoprosthesis in herpetic keratitis. Arch Ophthalmol. 2007;125:745-749.
14. Kang JJ, de la Cruz J, Cortina MS. Visual outcomes of Boston keratoprosthesis implantation as the primary penetrating corneal procedure. Cornea. 2012;31:1436-1440.
15. Sayegh RR, Ang LP, Foster CS, et al. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008;145:438-444.
16. Todani A, Gupta P, Colby K. Type I Boston keratoprosthesis with cataract extraction and intraocular lens placement for visual rehabilitation of herpes zoster ophthalmicus: the "KPro Triple". Br J Ophthalmol. 2009;93:119.
17. Dohlman C, Harissi-Dagher M, Khan BF, et al. Introduction to the use of the Boston keratoprosthesis. Expert Rev Ophthalmol. 2006;1:41-48.
18. Dohlman CH, Harissi-Dagher M. The Boston keratoprosthesis: a new threadless design. Digi J Ophthalmol. 2007;13:6.
19. Todani A, Ciolino JB, Ament JD, et al. Titanium back plate for a PMMA keratoprosthesis: clinical outcomes. Graefes Arch Clin Exp Ophthalmol. 2011;249:1515-1518.
20. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536-1547.
21. Bersudsky V, Blum-Hareuveni T, Rehany U, et al. The profile of repeated corneal transplantation. Ophthalmology. 2001;108:461-469.
22. Kremer I, Rajpal RK, Rapuano CJ, et al. Results of penetrating keratoplasty in aniridia. Am J Ophthalmol. 1993;115:317-320.
23. Gomes JA, Eagle RC Jr, Gomes AK, et al. Recurrent keratopathy after penetrating keratoplasty for aniridia. Cornea. 1996;15:457-462.
24. Solomon A, Ellies P, Anderson DF, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology. 2002;109:1159-1166.
25. Larkin DF. Corneal transplantation for herpes simplex keratitis. Br J Ophthalmol. 1998;82:107-108.
26. Ti SE, Scott JA, Janardhanan P, et al. Therapeutic keratoplasty for advanced suppurative keratitis. Am J Ophthalmol. 2007;143:755-762.
27. Chen WL, Wu CY, Hu FR, et al. Therapeutic penetrating keratoplasty for microbial keratitis in Taiwan from 1987 to 2001. Am J Ophthalmol. 2004;137:736-743.
28. Lomholt JA, Ehlers N. Graft survival and risk factors of penetrating keratoplasty for microbial keratitis. Acta Ophthalmol Scand. 1997;75: 418-422.
29. Tiller AM, Odenthal MT, Verbraak FD, et al. The influence of keratoplasty on visual prognosis in aniridia: a historical review of one large family. Cornea. 2003;22:105-110.
30. Cobo LM, Coster DJ, Rice NS, et al. Prognosis and management of corneal transplantation for herpetic keratitis. Arch Ophthalmol. 1980;98: 1755-1759.
31. Sivaraman KR, Hou JH, Allemann N, et al. Retroprosthetic membrane and risk of sterile keratolysis in patients with type I Boston keratoprosthesis. Am J Ophthalmol. 2013;155:814-822.
32. Ament JD, Spurr-Michaud SJ, Dohlman CH, et al. The Boston Keratoprosthesis: comparing corneal epithelial cell compatibility with titanium and PMMA. Cornea. 2009;28:808-811.
33. Cruzat A, Shukla AN, Dohlman CH, et al. Wound anatomy after type 1 Boston KPro using oversized back plates. Cornea. 2013;32:1531-1536.
34. Stacy RC, Jakobiec FA, Michaud NA, et al. Characterization of retrokeratoprosthetic membranes in the Boston type 1 keratoprosthesis. Arch Ophthalmol. 2011;129:310-316.
35. Kamyar R, Weizer JS, de Paula FH, et al. Glaucoma associated with Boston type I keratoprosthesis. Cornea. 2012;31:134-139.
36. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology. 2011;118:1543-1550.
37. Netland PA, Terada H, Dohlman CH. Glaucoma associated with keratoprosthesis. Ophthalmology. 1998;105:751-757.
38. Todani A, Behlau I, Fava MA, et al. Intraocular pressure measurement by radio wave telemetry. Invest Ophthalmol Vis Sci. 2011;52:9573-9580.
39. Harissi-Dagher M, Khan BF, Schaumberg DA, et al. Importance of nutrition to corneal grafts when used as a carrier of the Boston Keratoprosthesis. Cornea. 2007;26:564-568.
40. Dohlman CH, Dudenhoefer EJ, Khan BF, et al. Protection of the ocular surface after keratoprosthesis surgery: the role of soft contact lenses. CLAO J. 2002;28:72-74.
41. Utine CA, Tzu JH, Akpek EK. Clinical features and prognosis of Boston type I keratoprosthesis-associated corneal melt. Ocul Immunol Inflamm. 2011;19:413-418.
42. Nouri M, Terada H, Alfonso EC, et al. Endophthalmitis after keratoprosthesis: incidence, bacterial causes, and risk factors. Arch Ophthalmol. 2001;119:484-489.
43. Khan BF, Harissi-Dagher M, Khan DM, et al. Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin. 2007;47:61-71.
44. Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci. 2009;50:3346-3352.
45. Behlau I, Mukherjee K, Todani A, et al. Biocompatibility and biofilm inhibition of N,N-hexyl,methyl-polyethylenimine bonded to Boston Keratoprosthesis materials. Biomaterials. 2011;32:8783-8796.